Saturday 17 October 2026
Export JAZZ’s income statement to Excel — free account
Jazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
210.05
4.37
−2.04%
Follow JAZZ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 22.11% | 0.68% | (8.47%) | (8.80%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
7 | 6 | 5 | 5 | |
| 8.54% | 0.25% | (3.01%) | (3.03%) | ||
ROIC |
8.06% | (0.34%) | (3.72%) | (4.24%) | |
Return on Tangible Assets |
48.26% | 1.16% | (16.77%) | (21.41%) | |
Average Days of Receivables |
69.88 | 68.77 | 71.05 | 67.10 | |
Free Cash Flow per Share |
22.41 | 5.07 | 5.18 | 6.28 | |
Free Cash Flow |
1,416.54 | 313.74 | 316.14 | 380.97 | |
Capital Expenditures |
(244.54) | (1,020.44) | (1,039.64) | (1,010.86) | |
| Other line items | |||||
Cash ROIC |
12.48% | 2.46% | 2.61% | 3.35% | |
Accounts Receivable Turnover |
5.77 | 5.96 | 5.52 | 5.59 | |
Accounts Payable Turnover |
4.89 | 5.44 | 5.03 | 4.03 | |
Inventory Turnover |
1.12 | 1.15 | 1.12 | 0.94 | |
Average Days of Payables |
88.01 | 68.51 | 88.55 | 116.12 | |
Days of Inventory on Hand |
303.43 | 299.72 | 302.42 | 368.52 | |
Tax Rate |
0.29 | (1.14) | (0.43) | (0.48) | |
Research and Development Expense of Revenue |
17.73% | 17.98% | 18.34% | 19.46% | |
Selling, General and Administrative Expense of Revenue |
36.48% | 37.13% | 42.40% | 42.63% | |
Share Based Compensation of Revenue |
6.67% | 6.71% | 6.82% | 6.99% | |
Interest Coverage |
5.25 | (0.21) | (2.21) | (2.46) | |
Operating CF/Net income |
1.77 | 45.30 | (3.81) | (3.89) | |
Depreciation/Fixed assets |
3.39 | 3.51 | 3.48 | 3.63 | |
Capex/Depreciation |
(0.34) | (1.43) | (1.49) | (1.47) | |
Revenue per Share |
72.81 | 71.71 | 69.98 | 68.50 | |
Operating CF per Share |
26.28 | 21.55 | 22.23 | 22.93 | |
Capex per Share |
(3.87) | (16.49) | (17.05) | (16.65) | |
Capex to Sales |
0.05 | 0.23 | 0.24 | 0.24 |
Columns are period end dates